A liquid chromatography-mass spectrometry-based approach to characterize the substrate specificity of mammalian heparanase

Journal of Biological Chemistry

Volumn 289, Issue 49, 2014, Pages 34141-34151

  Mao, Yang ^a   Huang, Yu ^a   Buczek Thomas, Jo Ann ^a   Ethen, Cheryl M ^b   Nugent, Matthew A ^a,c   Wu, Zhengliang L ^b   Zaia, Joseph ^a,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b R and D Systems Inc   (United States)

^c University of Massachusetts Lowell   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING SITES; CELL PROLIFERATION; DISEASES; HYDRAULIC STRUCTURES; LIQUIDS; MAMMALS; MASS SPECTROMETRY;

CELLULAR PHENOTYPES; COMMON RECOGNITION; EXTRACELLULAR MATRICES; LIQUID CHROMATOGRAPHY - MASS SPECTROMETRIES; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MAMMALIAN HEPARANASE; SUBSTRATE SPECIFICITY; VASCULAR REMODELING;

LIQUID CHROMATOGRAPHY;

FIBROBLAST GROWTH FACTOR 2; HEPARANASE; OLIGOSACCHARIDE; BETA GLUCURONIDASE; HEPARAN SULFATE; RECOMBINANT PROTEIN; SDC4 PROTEIN, HUMAN; SYNDECAN 4;

ARTICLE; BINDING SITE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME DEGRADATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MITOGENESIS; MOLECULAR RECOGNITION; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; STRUCTURE ANALYSIS; SULFATION; TERMINAL SEQUENCE; ANIMAL; BOVINE; CARBOHYDRATE ANALYSIS; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETICS; HUMAN; LYMPHOCYTE; METABOLISM; MOLECULAR GENETICS; PIG; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

MAMMALIA;

ANIMALS; CARBOHYDRATE SEQUENCE; CATTLE; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; EXTRACELLULAR MATRIX; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; GLUCURONIDASE; HEPARITIN SULFATE; HUMANS; LYMPHOCYTES; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; SWINE; SYNDECAN-4; TANDEM MASS SPECTROMETRY;

EID: 84917710536     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.589630     Document Type: Article

References (43)

1. Kjellén, L., and Lindahl, U. (1991) Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60, 443-475
2. David, G. (1993) Integral membrane heparan sulfate proteoglycans. FASEB J. 7, 1023-1030
3. Sasisekharan, R., Shriver, Z., Venkataraman, G., and Narayanasami, U. (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2, 521-528
4. Bernfield, M., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., and Zako, M. (1999) Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729-777
5. Dowd, C. J., Cooney, C. L., and Nugent, M. A. (1999) Heparan sulfate mediates bFGF transport through basement membrane by diffusion with rapid reversible binding. J. Biol. Chem. 274, 5236-5244
6. Goldshmidt, O., Nadav, L., Aingorn, H., Irit, C., Feinstein, N., Ilan, N., Zamir, E., Geiger, B., Vlodavsky, I., and Katz, B. Z. (2002) Human heparanase is localized within lysosomes in a stable form. Exp. Cell Res. 281, 50-62
7. Zetser, A., Levy-Adam, F., Kaplan, V., Gingis-Velitski, S., Bashenko, Y., Schubert, S., Flugelman, M. Y., Vlodavsky, I., and Ilan, N. (2004) Processing and activation of latent heparanase occurs in lysosomes. J. Cell Sci. 117, 2249-2258
8. Vlodavsky, I., Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R., Ishai- Michaeli, R., Bitan, M., Pappo, O., Peretz, T., Michal, I., Spector, L., and Pecker, I. (1999) Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5, 793-802
9. Hulett, M. D., Freeman, C., Hamdorf, B. J., Baker, R. T., Harris, M. J., and Parish, C. R. (1999) Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 5, 803-809
10. Nakajima, M., Irimura, T., Di Ferrante, N., and Nicolson, G. L. (1984) Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J. Biol. Chem. 259, 2283-2290
11. Nakajima, M., Irimura, T., Di Ferrante, D., Di Ferrante, N., and Nicolson, G. L. (1983) Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science 220, 611-613
12. Vlodavsky, I., and Friedmann, Y. (2001) Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 108, 341-347
13. Vlodavsky, I., Elkin, M., Abboud-Jarrous, G., Levi-Adam, F., Fuks, L., Shafat, I., and Ilan, N. (2008) Heparanase: one molecule with multiple functions in cancer progression. Connect. Tissue Res. 49, 207-210
14. Vlodavsky, I., Miao, H. Q., Medalion, B., Danagher, P., and Ron, D. (1996) Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev. 15, 177-186
15. Ishai-Michaeli, R., Eldor, A., and Vlodavsky, I. (1990) Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Regul. 1, 833-842
16. Vlodavsky, I., Bar-Shavit, R., Ishai-Michaeli, R., Bashkin, P., and Fuks, Z. (1991) Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem. Sci. 16, 268-271
17. Nadir, Y., Vlodavsky, I., and Brenner, B. (2008) Heparanase, tissue factor, and cancer. Semin. Thromb. Hemost. 34, 187-194
18. Ramani, V. C., Purushothaman, A., Stewart, M. D., Thompson, C. A., Vlodavsky, I., Au, J. L., and Sanderson, R. D. (2013) The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. 280, 2294-2306
19. Pikas, D. S., Li, J.-P., Vlodavsky, I., and Lindahl, U. (1998) Substrate specificity of heparanases from human hepatoma and platelets. J. Biol. Chem. 273, 18770-18777
20. Okada, Y., Yamada, S., Toyoshima, M., Dong, J., Nakajima, M., and Sugahara, K. (2002) Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. J. Biol. Chem. 277, 42488-42495
21. Peterson, S. B., and Liu, J. (2010) Unraveling the specificity of heparanase utilizing synthetic substrates. J. Biol. Chem. 285, 14504-14513
22. Peterson, S., and Liu, J. (2012) Deciphering mode of action of heparanase using structurally defined oligosaccharides. J. Biol. Chem. 287, 34836-34843
23. Shi, X., and Zaia, J. (2009) Organ-specific heparan sulfate structural phenotypes. J. Biol. Chem. 284, 11806-11814
24. Lawrence, R., Lu, H., Rosenberg, R. D., Esko, J. D., and Zhang, L. (2008) Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat. Methods 5, 291-292
25. Staples, G. O., Bowman, M. J., Costello, C. E., Hitchcock, A. M., Lau, J. M., Leymarie, N., Miller, C., Naimy, H., Shi, X., and Zaia, J. (2009) A chipbased amide-HILIC LC/MS platform for glycosaminoglycan glycomics profiling. Proteomics 9, 686-695
26. Staples, G. O., Naimy, H., Yin, H., Kileen, K., Kraiczek, K., Costello, C. E., and Zaia, J. (2010) Improved hydrophilic interaction chromatography LC/MS of heparinoids using a chip with postcolumn makeup flow. Anal. Chem. 82, 516-522
27. Naimy, H., Buczek-Thomas, J. A., Nugent, M. A., Leymarie, N., and Zaia, J. (2011) Highly sulfated nonreducing end-derived heparan sulfate domains bind fibroblast growth factor-2 with high affinity and are enriched in biologically active fractions. J. Biol. Chem. 286, 19311-19319
28. Chambers, M. C., Maclean, B., Burke, R., Amodei, D., Ruderman, D. L., Neumann, S., Gatto, L., Fischer, B., Pratt, B., Egertson, J., Hoff, K., Kessner, D., Tasman, N., Shulman, N., Frewen, B., Baker, T. A., Brusniak, M. Y., Paulse, C., Creasy, D., Flashner, L., Kani, K., Moulding, C., Seymour, S. L., Nuwaysir, L. M., Lefebvre, B., Kuhlmann, F., Roark, J., Rainer, P., Detlev, S., Hemenway, T., Huhmer, A., Langridge, J., Connolly, B., Chadick, T., Holly, K., Eckels, J., Deutsch, E. W., Moritz, R. L., Katz, J. E., Agus, D. B., MacCoss, M., Tabb, D. L., and Mallick, P. (2012) A cross-platform toolkit for mass spectrometry and proteomics. Nat. Biotechnol. 30, 918-920
29. Maxwell, E., Tan, Y., Tan, Y., Hu, H., Benson, G., Aizikov, K., Conley, S., Staples, G. O., Slysz, G. W., Smith, R. D., and Zaia, J. (2012) GlycReSoft: a software package for automated recognition of glycans from LC/MS data. PloS One 7, e45474
30. Huang, Y., Shi, X., Yu, X., Leymarie, N., Staples, G. O., Yin, H., Killeen, K., and Zaia, J. (2011) Improved liquid chromatography-MS/MS of heparan sulfate oligosaccharides via chip-based pulsed makeup flow. Anal. Chem. 83, 8222-8229
31. Ernst, S., Langer, R., Cooney, C. L., and Sasisekharan, R. (1995) Enzymatic degradation of glycosaminoglycans. Crit. Rev. Biochem. Mol. Biol. 30, 387-444
32. Wu, Z. L., and Lech, M. (2005) Characterizing the non-reducing end structure of heparan sulfate. J. Biol. Chem. 280, 33749-33755
33. Gilat, D., Hershkoviz, R., Goldkorn, I., Cahalon, L., Korner, G., Vlodavsky, I., and Lider, O. (1995) Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH. J. Exp. Med. 181, 1929-1934
34. Schlessinger, J., Plotnikov, A. N., Ibrahimi, O. A., Eliseenkova, A. V., Yeh, B. K., Yayon, A., Linhardt, R. J., and Mohammadi, M. (2000) Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6, 743-750
35. Podyma-Inoue, K. A., Yokote, H., Sakaguchi, K., Ikuta, M., and Yanagishita, M. (2002) Characterization of heparanase from a rat parathyroid cell line. J. Biol. Chem. 277, 32459-32465
36. Bai, X., Bame, K. J., Habuchi, H., Kimata, K., and Esko, J. D. (1997) Turnover of heparan sulfate depends on 2-O-sulfation of uronic acids. J. Biol. Chem. 272, 23172-23179
37. Yamada, S., Sakamoto, K., Tsuda, H., Yoshida, K., Sugahara, K., Khoo, K.-H., Morris, H. R., and Dell, A. (1994) Structural studies on the tri- and tetrasaccharides isolated from porcine intestinal heparin and characterization of heparinase/heparitinases using them as substrates. Glycobiology 4, 69-78
38. Horowitz, A., Tkachenko, E., and Simons, M. (2002) Fibroblast growth factor-specific modulation of cellular response by syndecan-4. J. Cell Biol. 157, 715-725
39. Zhang, Z., Coomans, C., and David, G. (2001) Membrane heparan sulfate proteoglycan-supported FGF2-FGFR1 signaling: evidence in support of the "cooperative end structures" model. J. Biol. Chem. 276, 41921-41929
40. Vlodavsky, I., Beckhove, P., Lerner, I., Pisano, C., Meirovitz, A., Ilan, N., and Elkin, M. (2012) Significance of heparanase in cancer and inflammation. Cancer Microenviron. 5, 115-132
41. Purushothaman, A., Hurst, D. R., Pisano, C., Mizumoto, S., Sugahara, K., and Sanderson, R. D. (2011) Heparanase-mediated loss of nuclear syndecan- 1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J. Biol. Chem. 286, 30377-30383
42. Varki, A., Cummings, R. D., Esko, J. D., Freeze, H. H., Stanley, P., Marth, J. D., Bertozzi, C. R., Hart, G. W., and Etzler, M. E. (2009) Symbol nomenclature for glycan representation. Proteomics 9, 5398-5399
43. Domon, B., and Costello, C. E. (1988) A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. Glycoconjugate J. 5, 397-409